



July 1, 2025

To whom it may concern

Company Name: KIRIN HOLDINGS COMPANY, LIMITED

Name and Title of Representative: Takeshi Minakata, President & COO

Code Number: 2503 (Tokyo Stock Exchange, Prime Section)

Head Office:

4-10-2, Nakano, Nakano-ku, Tokyo 164-0001, Japan

Name and Title of Contact Person:

Hidefumi Matsuo

General Manager of Finance Department

Telephone Number: +81-3-6837-7015

(Progress of disclosed matters) Completion of Transfer of Part of Kyowa Hakko Bio's Business

Kirin Holdings Company, Limited (President and COO: Takeshi Minakata) and Kyowa Hakko Bio Co., Ltd. (President and Representative Director: Koji Fukada; hereinafter "Kyowa Hakko Bio") announced "Kyowa Hakko Bio to Transfer Part of its Business and Recognize Business Structure Improvement Expenses" on November 22, 2024. We hereby inform you that the transfer procedures related to the amino acid and Human Milk Oligosaccharide businesses (hereinafter "certain businesses") of Kyowa Hakko Bio have been completed as of July 1, 2025, as initially scheduled for the fourth quarter of 2025.

1. Summary

The transfer of certain businesses from Kyowa Hakko Bio to a special purpose company, a subsidiary of Meihua Holdings Group Co., Ltd., a leading bio-manufacturing company in China, has been completed.

2. Date of Completion of Business Transfer

July 1, 2025

3. Future Outlook

The impact of this business transfer on our future consolidated results for the current fiscal year is currently under review. Should any matters arise that require disclosure, we will promptly make an announcement

- END -